Kailera Therapeutics to Present at ObesityWeek 2026
Key Highlights
- ➤Kailera will present Phase 3 KaiNETIC ribupatide trial designs at ObesityWeek 2026
- ➤Global Phase 3 KaiNETIC program evaluates once-weekly ribupatide injection for obesity
- ➤Kailera plans global Phase 3 ribupatide oral trials in obesity in first half of 2027
- ➤Hengrui Pharma will present Phase 3 HARBOR findings for oral safiglipron
- ➤Hengrui submitted a China NDA for ribupatide injection in long-term weight management
Expert Statements
Scott Wasserman, M.D., Chief Medical Officer of Kailera Therapeutics
“People living with obesity have diverse and often highly individualized treatment needs, underscoring the importance of developing new therapeutic options.”
Scott Wasserman, M.D., Chief Medical Officer of Kailera Therapeutics
“The research we are presenting at ObesityWeek reflects both the rigor of our clinical development program and our focus on better understanding the real-world obesity landscape and how our differentiated GLP-1-based pipeline can address unmet patient needs.”
* Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum * Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity.
“People living with obesity have diverse and often highly individualized treatment needs, underscoring the importance of developing new therapeutic options,” said Scott Wasserman, M.D., Chief Medical Officer of Kailera Therapeutics. “The research we are presenting at ObesityWeek reflects both the rigor of our clinical development program and our focus on better understanding the real-world obesity landscape and how our differentiated GLP-1-based pipeline can address unmet patient needs.”
Get started
Create a free account to read the full story.